As Xarelto Lawsuit Numbers Increase Portola Receives PDUFA Action Date For August 2016 Possible Antidote

March 29, 2016 – – BloodThinnerHelp.com reports on the recently granted Precription Drug User Fee Act (PDUFA) action date for Portola Pharmaceuticals’ developing anticoagulant antidote, Andexanet Alfa. According to reports from seekingalpha.com, Portola Pharmaceuticals was recently granted a PDUFA from the FDA for the developing antidote for August 17, 2016. While the antidote has yet to be approved, the new antidote could have the potential to change the leaders in the anticoagulant market by changing the types of anticoagulants preferred by doctors, according to the report. The new drug is expected to reverse the effects of anticoagulants including blood-thinning drugs like Xarelto.

Though the new drug may counter the adverse side effects many have associated with Xarelto, thousands of patients have already claimed to have been negatively affected by the drug.

Xarelto, manufactured by Bayer AG and Johnson & Johnson, was first introduced in the U.S. when it was approved by the FDA in 2011 for preventing blood clots and deep vein thrombosis in patients undergoing knee and hip replacements, atrial fibrillation, and general use in reducing the recurrence of blood clots, and stent thrombosis in patients with acute coronary syndrome. The first case alleging that the drug was the cause of death because of uncontrollable bleeding was filed in 2014. Other injuries that plaintiffs have associated with Xarelto have included stroke, heart attack, internal bleeding, gastrointestinal bleeding, epidural hematoma, rectal bleeding and pulmonary embolisms.

For more effective handling of the nearly 3,000 cases that have been filed federally, a multidistrict litigation panel was formed in New Orleans, Louisiana. Presiding over those cases will be Judge Eldon E. Fallon, who has set dates for the bellwether trials in for those cases to begin in February 2017. About 40 cases have been chosen.

While those cases approach a trial date, Attorney Joseph Osborne is working to ensure that those individuals who believe they have been negatively affected by the drug have the opportunity to fully explore their legal rights. Qualifying individuals may be entitled to legal action and substantial financial compensation. Osborne is currently offering complimentary legal consultations for affected parties.

To learn more about Xarelto, or to ask questions, contact Joseph Osborne, Esq. at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008939